{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-052707","form_type":"8-K","ticker":"FBLG","cik":"0001958777","company_name":"FibroBiologics, Inc.","filed_at":"2024-12-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:10.440425+00:00","generated_at":"2026-05-28T22:10:54.669124+00:00","sec_items":["1.01","2.03","3.02","5.02","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"FibroBiologics closes $5M second tranche of convertible note; grants CEO/CSO options","bullets":["Second $5M tranche under SEPA with YA II PN (Yorkville) funded Dec 30, 2024; convertible note bears 0% interest (18% on default).","Conversion price is lower of $2.84/share or 94% of 5-day VWAP (with floor). Matures Dec 20, 2025; extendable by the company.","Company granted CEO Pete O'Heeron options for 406,339 shares and CSO Hamid Khoja options for 176,200 shares at $2.36/share.","Options vest 1/4 on Dec 27, 2025, then monthly over 36 months; issued under 2022 Stock Plan.","Net proceeds from the SEPA (up to $25M over 2 years) will be used for general corporate purposes."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-052707","json":"https://secwatch.observer/filing/0001493152-24-052707.json","markdown":"https://secwatch.observer/filing/0001493152-24-052707.md","text":"https://secwatch.observer/filing/0001493152-24-052707.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1958777/000149315224052707/0001493152-24-052707-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1958777/000149315224052707/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T22:10:54.669124+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}